Desmopressin: evidence, FDA status and research

A hormone drug for excess urine, bleeding disorders and bedwetting. Controlled trials back those uses; the online memory-booster claim has no support.

Sold for

Desmopressin surfaces online as a memory booster and a nootropic because vasopressin acts in the brain, and as a shortcut for night-time urination; none of that is on the label.

Studies say

Approval for diabetes insipidus, bleeding disorders and nocturia rests on controlled trials and decades of use, an A for those indications, while the only consistent safety story is dangerously low sodium when fluid intake is not restricted.

Why grade A. Desmopressin has been the standard treatment for central diabetes insipidus for nearly fifty years, and the nocturia indications were approved in 2017 and 2018 on randomized placebo-controlled trials summarized on their labels. The citations here are labels and regulatory records, not primary trial papers; the largest trial they describe is Nocdurna's three-month study in 237 women. ²³

FDA. Desmopressin is FDA-approved, first in 1978 as DDAVP, for central diabetes insipidus, for temporary excessive urination after pituitary surgery or head injury, for bleeding control in mild hemophilia A and type 1 von Willebrand disease, and for primary nocturnal enuresis (bedwetting) in children; Nocdurna, a sublingual tablet approved in 2018, treats nocturia due to nocturnal polyuria in adults. The Noctiva nasal spray approved in 2017 for nocturia has been discontinued, and the Stimate nasal spray for bleeding disorders was recalled in 2020 and was still off the market in 2023. ²³¹⁴

Written from 4 cited sources. Fact-checked 2026-10-27: 16 claims checked, 5 corrected. Last refreshed 2026-10-27. Not physician reviewed.

What this means for you

What people take it for: Excess urine, bleeding disorders, bedwetting, and night-time urination.
Can a US doctor prescribe it?: Yes, FDA approved for diabetes insipidus, some bleeding disorders, bedwetting and night-time urination.
Properly tested in people?: Yes, in large controlled trials for its approved uses. The largest trial in the article had 237 women.

Evidence checklist

Randomised controlled trial Placebo-controlled trials for nocturiayes
Human study over 100 people Trial sizes not given in the citationsno information
More than one research group Used and studied for decades across settingsyes
Clinical outcomes, not surrogate markers Urine output, night voids, factor VIII levelsyes
Human safety data beyond case reports Boxed warning for low sodiumyes

Drawn from the cited studies below. A dash means the sources give no information.

What it is

Desmopressin is a synthetic analog of vasopressin (antidiuretic hormone), the nine-amino-acid pituitary peptide that tells the kidneys to retain water. Two changes, removing an amino group at one end and swapping L-arginine for D-arginine, make it last longer and strip out most of vasopressin's blood-pressure-raising activity, leaving a drug that acts mainly on the kidney. ²

It has been sold in the United States since 1978 as DDAVP in injection, nasal spray and tablet forms, with generics. Later products were Stimate, a high-concentration nasal spray for bleeding disorders; Noctiva, a low-dose nasal spray for nocturia approved in 2017 and since discontinued; and Nocdurna, a tablet that dissolves under the tongue, approved in 2018 for nocturia. ²¹³

How it works

Desmopressin binds vasopressin V2 receptors in the collecting ducts of the kidney, which moves water channels (aquaporins) into the cell membrane so water is reabsorbed and urine becomes concentrated. In central diabetes insipidus, where the pituitary fails to make vasopressin, this replaces the missing signal; in nocturia and bedwetting it reduces the volume of urine made overnight. The same V2 receptor on blood-vessel lining cells triggers release of stored von Willebrand factor and factor VIII, which is why a dose before a procedure can raise clotting-factor levels severalfold in people with mild hemophilia A or type 1 von Willebrand disease. ²⁴

What human research shows

The DDAVP label describes controlled studies in central diabetes insipidus showing reduced urine output and increased urine concentration, and studies in hemophilia A and von Willebrand disease showing factor VIII activity rising to levels sufficient for minor surgery in patients whose baseline level is above 5%. ²

Nocdurna's approval rested on two three-month randomized placebo-controlled trials, one in 237 women and one in 230 men, all of whom woke at least twice a night to urinate. Both showed fewer night-time voids and more nights with at most one void than placebo; the effect beyond placebo was modest, and the label sets different doses for men and women because women are more prone to low sodium. ³

Study	Model	Finding
DDAVP prescribing information	Regulatory summary of controlled studies in diabetes insipidus and bleeding disorders	Reduces urine volume in central diabetes insipidus; raises factor VIII and von Willebrand factor in mild hemophilia A and type 1 von Willebrand disease. ²
Nocdurna prescribing information	Humans, two randomized placebo-controlled trials in adults with nocturia	Fewer night-time voids than placebo; boxed warning for hyponatremia. ³
Stimate recall, 2020	Regulatory action, Ferring US	Manufacturing suspended and nasal sprays recalled over a seal defect that let the solution evaporate and concentrate; still unavailable in 2023. ⁴

Safety

The one serious risk is hyponatremia, low blood sodium, which happens when desmopressin stops the kidneys excreting water and the person keeps drinking. Severe cases cause seizures, coma and death. Nocdurna carries a boxed warning for it, as Noctiva did, and the label requires a sodium check before starting and within the first week, and contraindicates use in people with kidney impairment, heart failure, uncontrolled hypertension or on loop diuretics or systemic or inhaled glucocorticoids. ³¹

For the older indications the same rule applies: fluid intake has to be limited in the hours around a dose, especially in children treated for bedwetting and in elderly patients. Nasal forms can cause congestion and nosebleeds; the 2020 Stimate recall followed a packaging seal problem that let the solution evaporate, which could expose patients to a higher concentration of desmopressin than labeled. Headache, nausea and facial flushing are the common minor effects. ²⁴

Questions for your clinician

How will my sodium be checked before and after I start?
Do my kidneys, heart or medicines raise the hyponatremia risk?
What fluid limits should I follow while taking it?

Questions people ask

Is desmopressin FDA-approved?

Yes, since 1978. Indications include central diabetes insipidus, post-surgical polyuria, mild hemophilia A, type 1 von Willebrand disease, childhood bedwetting and, for the Nocdurna tablet, adult nocturia. ²³

What happened to Noctiva and Stimate?

Noctiva, the 2017 nocturia nasal spray, was discontinued by its maker. Stimate, the bleeding-disorder nasal spray, was recalled in 2020 after a seal defect let the solution evaporate and concentrate, and it was still unavailable in 2023, when a compounding facility was making a substitute nasal spray. ¹⁴

Why is low sodium the main warning?

Desmopressin stops the kidneys from passing water. If a person keeps drinking normally the retained water dilutes blood sodium, and severe dilution causes seizures. The nocturia products carry a boxed warning and require sodium monitoring. ³

Does desmopressin improve memory?

Vasopressin does act in the brain, which is where the nootropic claim comes from, but desmopressin was engineered to act on the kidney and no memory indication has been studied to approval. None of the cited sources address it. ²

Citations

Drugs.com: Noctiva (desmopressin nasal spray), discontinued drugs.com
DDAVP (desmopressin acetate) prescribing information drugs.com
Nocdurna (desmopressin acetate sublingual tablets) prescribing information drugs.com
National Bleeding Disorders Foundation: updates on the desmopressin nasal spray recall bleeding.org